T2 Biosystems Presents Data From Two Studies Evaluating T2MR in Hemostasis at the International Society on Thrombosis and Haemostasis Annual Congress

T2 Biosystems Presents Data From Two Studies Evaluating T2MR in Hemostasis at the International Society on Thrombosis and Haemostasis Annual Congress

June 23, 2015

Rapid, Accurate Multiplex Results Achieved Using Low Blood Volumes on a Single Easy-to-Use Instrument

Joule Expands Intellectual Property on Direct Conversion of CO2 to Hydrocarbons

Joule Expands Intellectual Property on Direct Conversion of CO2 to Hydrocarbons

June 16, 2015

Bedford, Mass -- Joule, the pioneer of liquid fuels from recycled CO2, today announced the issuance of an additional patent on the direct, continuous production of hydrocarbon fuels – extending its ability to target the highest-value molecules of the petroleum distillation process and generate them on demand from sunlight and CO2.

U.S. Patent #9,034,629, issued on May 19, covers both the cyanobacterium and the process for directly converting CO2 into medium-chain alkanes, which are the molecular basis of diesel, jet fuel and gasoline.

Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

June 15, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that new study findings involving the use of dalantercept to block the activin receptor-like kinase 1 (ALK1) pathway for the treatment of metastatic breast cancer were published in the June 15th issue (volume 75, #12) of Cancer Research, a journal of the American Association for Cancer Research.

Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors

Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors

June 11, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company developing a novel class of Ecobiotic® drugs designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that Dennis Ausiello, M.D., has been elected to the company’s board of directors. Dr.

Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

June 12, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company, today announced that SER-109 (Firmacute Eubacterial Spores, Purified Suspension, Encapsulated), its lead product candidate under investigation for the prevention of recurrent Clostridium difficile infection (CDI) in adults, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA).

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

June 12, 2015

 - In lower risk myelodysplastic syndromes patients, longer-term treatment with luspatercept led to sustained increases in hemoglobin levels and transfusion independence -

BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

June 12, 2015

 - Potential for combined Manocept and Accurin platforms to target the tumor microenvironment -

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

June 12, 2015

 IDH2-Mutant Inhibitor Shows Durable Responses of More than 15 Months in Patients with Advanced Acute Myeloid Leukemia (AML) and Other Blood Cancers

Proof-of-Concept Demonstrated in Myelodysplastic Syndrome (MDS) and Untreated AML

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

June 12, 2015

 IDH1-Mutant Inhibitor Shows Durable Responses of Up to 11 Months in Patients with Advanced Acute Myeloid Leukemia (AML) and Other Blood Cancers

Three Expansion Cohorts and Global Registration-Enabling Program Remain on Track

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

June 12, 2015

 Data Support Activation of DRIVE PK, a Global Phase 2 Study of AG-348 in PK Deficiency Patients

First Data from Natural History Study of PK Deficiency Characterize Severity of this Rare Genetic Disease